ERRATUM

Combined Diagnostic Significance of Preoperative Serum β 2-Microglobulin and Routine Blood Test in Patients with High-Grade Glioma and Solitary Brain Metastasis [Erratum]

Li L, Bu X, Wu B, et al. *Cancer Manag Res.* 2020;12:11735—11742.

The authors have advised that Table 1 on page 11737 and Table 2 on page 11739 are the versions uploaded during

the initial submission stage instead of the final revised versions. These errors were introduced by the Editorial staff during the publication process. The correct Tables 1 and 2 are shown below.

Table I Clinical Characteristic of the Patients with HGG and sBM

Parameters	HGG (n=127)	sBM (n=174)	Р	
Age (years)	56.00 (50.00, 65.00)	63.00 (53.00, 68.00)		
Gender (male/female)	67/60	102/72	0.347	
β 2-m (μg/L)	1771.00 (1544.00, 2063.00)	2067.00 (1649.75, 2701.00)	0.000	
WBC count (×10 ⁹ /L)	6.00 (5.10, 7.50)	6.10 (5.00, 7.80)	0.905	
Neutrophils (×10 ⁹ /L)	3.90 (3.10, 5.00)	4.20 (3.20, 5.70)	0.174	
Lymphocytes (×10 ⁹ /L)	1.60 (1.30, 2.10)	1.40 (1.10, 1.80)	0.000	
Monocytes (×10 ⁹ /L)	0.40 (0.30, 0.50)	0.40 (0.30, 0.60)	0.380	
Platelets (×10 ⁹ /L)	207.00 (166.00, 237.00)	204.50 (159.00, 240.25)	0.670	
RDW (%)	12.80 (12.30, 13.20)	13.00 (12.40, 13.50)	0.052	
PDW (%)	16.10 (15.80, 16.40)	16.00 (15.70, 16.30)	0.305	
NLR	2.38 (1.84, 3.27)	3.00 (2.20, 4.39)	0.000	
MLR	0.23 (0.19, 0.30)	0.29 (0.21, 0.40)	0.000	

Notes: Data were presented as median (25th, 75th percentile).

Abbreviations: HGG, high grade glioma; sBM, solitary brain metastasis; β2-m, β2-microglobulin; WBC, white blood cell; RDW, red cell distribution width; PDW, platelet distribution width; NLR, neutrophil/lymphocyte ratio; MLR, monocyte/lymphocyte ratio.

Table 2 Diagnostic Value of Prec	operative Age, β 2-m, NLR, MLR a	and Their Combinations in Pa	atients with HGG and sBM
----------------------------------	--	------------------------------	--------------------------

Markers	Formula	Cut-off	AUC	95% CI	Sensitivity (%)	Specificity (%)
Age (years)		56.50	0.625	0.561-0.689	70.70	52.85
β2-m (μg/L)		1932.50	0.655	0.594-0.717	58.05	72.36
NLR		2.45	0.634	0.571-0.698	71.26	52.85
MLR		0.28	0.622	0.559-0.686	56.32	71.54
Age+β2-m	-4.262+0.049*Age+0.01*β2-m	0.628	0.683	0.623-0.742	50.57	82.11
Age+NLR	-4.349+0.065*Age+0.212*NLR	0.541	0.683	0.622-0.744	71.26	43.90
Age+MLR	-4.291+0.064*Age+2.263*MLR	0.650	0.673	0.612-0.734	47.13	82.11
β 2-m+NLR	-3.311+0.001*β2-m+0.225*NLR	0.621	0.720	0.663-0.778	55.17	86.18
β 2-m+MLR	-2.926+0.001*β2-m+2.282*MLR	0.592	0.698	0.638-0.757	57.47	80.49
NLR+MLR	-0.923+1.514*MLR+0.136*NLR	0.554	0.634	0.571-0.697	59.20	67.48
Age+ β 2-m+NLR	-5.185+0.048*Age+0.001*β2-m+0.235*NLR	0.586	0.729	0.672-0.785	64.37	75.61
Age+ β 2-m+MLR	-4.894+0.049*Age+0.001*β2-m+2.145*MLR	0.569	0.716	0.658-0.773	65.52	72.36
Age+NLR+MLR	-4.470+0.064*Age+1.199*MLR+0.146*NLR	0.541	0.687	0.627-0.747	75.29	55.28
β 2-m+NLR+MLR	-3.334+0.001*β2-m+0.219*NLR 0.631*MLR	0.619	0.720	0.663-0.777	56.32	84.55
Age+β2-m+NLR	-5.213+0.048*Age+0.001*β2-m+0.201*NLR	0.600	0.731	0.675-0.788	60.92	77.24
+MLR	+0.594*MLR					

Abbreviations: HGG, high grade glioma; sBM, solitary brain metastasis; β 2-m, β 2-microglobulin; NLR, neutrophil/lymphocyte ratio; MLR, monocyte/lymphocyte ratio; AUC, area under the curve.



Cancer Management and Research 2021:13 3227-3228

© 2021 Li et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution — Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-m/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

Cancer Management and Research

Publish your work in this journal

Cancer Management and Research is an international, peer-reviewed open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient.

The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/cancer-management-and-research-journal

Dovepress